Timo Sorsa
Research Subjects
Timo Sorsa has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Päivi Mäntylä
Institute of Dentistry University of Eastern Finland Kuopio Finland
3 shared publications Tuula Salo
Departments of Oral Diagnostics and Medicine, and Pathology, University of Oulu, Oulu, Finland
3 shared publicationsDenis F. Kinane
Department of Periodontology, University Dental Hospital and School, University of Glasgow, Glasgow, UK, now at University of Louisville School of Dentistry, Kentucky, KY, USA
2 shared publicationsEmma Pirilä
Department of Oral and Maxillofacial Diseases, Biomedicum and Oral Pathology Unit, Laboratory Diagnostics, Helsinki University Central Hospital (HUCH), University of Helsinki, Orton Research Institute and the Orthopaedic Hospital of Invalid Foundation, Helsinki, Finland
2 shared publicationsKaiu Prikk
Institute of Experimental and Clinical Medicine, Tallinn, Estonia
2 shared publications- Olli Teronen
Department of Oral Medicine, Helsinki University Central Hospital Biomedicum, University of Helsinki, Helsinki, Finland
2 shared publications
Latest Publications
- 19 December 2003
- Published by Wiley in Oral Diseases
- Vol. 10 (1) , 32-35
Chlamydia pneumoniae together with collagenase‐2 (MMP‐8) in periodontal lesions
Objective: Dental infections may be associated with subsequent atherosclerosis. In this regard we wanted to study if traces of Chlamydia pneumoniae can be found from deep periodontal pockets characterized with elevated collagenase‐2 [matrix metalloproteinase (MMP)‐8] levels in gingival crevicular fluid (GCF). Chlamydia pneumoniae has not previously been found to infect the oral cavity.Subjects and methods: Subgingival samples of dental plaque were collected from 31 teeth in 12 adult periodontitis patients by means of sterile curettes and examined for C. pneumoniae using a quantitative PCR technique. GCF samples were also collected and assayed by an immunofluorometric assay (IFMA) for MMP‐8.Results: Chlamydia pneumoniae RNA was demonstrated in a sample from one of the patients studied. Periodontal treatment eliminated the C. pneumoniae from the patient's subgingival dental plaque as well as reduced GCF MMP‐8 level.Conclusions: Our findings suggest that C. pneumoniae, which is not normally thought to be involved in periodontitis, can be found in dental plaque.
- 19 December 2003
- Published by Wiley in Oral Diseases
- Vol. 10 (1) , 32-35
Chlamydia pneumoniae together with collagenase‐2 (MMP‐8) in periodontal lesions
Objective: Dental infections may be associated with subsequent atherosclerosis. In this regard we wanted to study if traces of Chlamydia pneumoniae can be found from deep periodontal pockets characterized with elevated collagenase‐2 [matrix metalloproteinase (MMP)‐8] levels in gingival crevicular fluid (GCF). Chlamydia pneumoniae has not previously been found to infect the oral cavity.Subjects and methods: Subgingival samples of dental plaque were collected from 31 teeth in 12 adult periodontitis patients by means of sterile curettes and examined for C. pneumoniae using a quantitative PCR technique. GCF samples were also collected and assayed by an immunofluorometric assay (IFMA) for MMP‐8.Results: Chlamydia pneumoniae RNA was demonstrated in a sample from one of the patients studied. Periodontal treatment eliminated the C. pneumoniae from the patient's subgingival dental plaque as well as reduced GCF MMP‐8 level.Conclusions: Our findings suggest that C. pneumoniae, which is not normally thought to be involved in periodontitis, can be found in dental plaque.
- 26 June 2003
- Published by Wiley in Journal of Periodontal Research
- Vol. 38 (4) , 436-439
Gingival crevicular fluid collagenase‐2 (MMP‐8) test stick for chair‐side monitoring of periodontitis
Background: A rapid chair‐side test based on the immunological detection of elevated levels of collagenase‐2 (matrix metalloproteinase‐8, MMP‐8) in gingival crevicular fluid (GCF) was developed to identify and monitor the course and treatment of adult periodontitis.Methods: MMP‐8 was determined in GCF from periodontitis (11 patients, 90 sites), gingivitis (10 patients, 58 sites) and healthy control (8 patients, 59 sites) sites (i) by a test stick incorporating monoclonal antibodies to two epitopes on MMP‐8 and (ii) by measuring MMP‐8 concentration by a quantitative immunofluorometric assay. Patients with adult periodontitis were treated by scaling and root planing (SRP) and received oral hygiene instructions. GCF MMP‐8 testing and clinical measurements were done before and after SRP.Results: MMP‐8 GCF levels and chair‐side test differentiated periodontitis from gingivitis and healthy control sites. MMP‐8 GCF levels > 1 mg/l and positive chair‐side test identified especially severe periodontitis sites. A positive and negative test stick result, the outcome of which was rapidly detectable in 5 mins, in GCF correlated well with MMP‐8 immunofluorometric assay analysis from the collected GCF samples and the severity of periodontitis. Scaling and root planing reduced the MMP‐8 levels in severe periodontitis sites with positive MMP‐8 test and gingival probing pocket depth (PD) > 5 mm before treatment. The test stick result and the quantitative assay were discrepant in only 18 of the 207 sites tested, thus agreement was very good (κ = 0.81). With a threshold of 1 mg/l MMP‐8 activity the chair‐side test provided a sensitivity of 0.83 and specificity of 0.96 (n = 207).Conclusion: The MMP‐8 test can be used to differentiate periodontitis from gingivitis and healthy sites as well as to monitor treatment of periodontitis. A reduction in GCF MMP‐8 levels and a change in test stick result provide a means to optimize patient control during maintenance of periodontal treatment.
- 26 June 2003
- Published by Wiley in Journal of Periodontal Research
- Vol. 38 (4) , 436-439
Gingival crevicular fluid collagenase‐2 (MMP‐8) test stick for chair‐side monitoring of periodontitis
Background: A rapid chair‐side test based on the immunological detection of elevated levels of collagenase‐2 (matrix metalloproteinase‐8, MMP‐8) in gingival crevicular fluid (GCF) was developed to identify and monitor the course and treatment of adult periodontitis.Methods: MMP‐8 was determined in GCF from periodontitis (11 patients, 90 sites), gingivitis (10 patients, 58 sites) and healthy control (8 patients, 59 sites) sites (i) by a test stick incorporating monoclonal antibodies to two epitopes on MMP‐8 and (ii) by measuring MMP‐8 concentration by a quantitative immunofluorometric assay. Patients with adult periodontitis were treated by scaling and root planing (SRP) and received oral hygiene instructions. GCF MMP‐8 testing and clinical measurements were done before and after SRP.Results: MMP‐8 GCF levels and chair‐side test differentiated periodontitis from gingivitis and healthy control sites. MMP‐8 GCF levels > 1 mg/l and positive chair‐side test identified especially severe periodontitis sites. A positive and negative test stick result, the outcome of which was rapidly detectable in 5 mins, in GCF correlated well with MMP‐8 immunofluorometric assay analysis from the collected GCF samples and the severity of periodontitis. Scaling and root planing reduced the MMP‐8 levels in severe periodontitis sites with positive MMP‐8 test and gingival probing pocket depth (PD) > 5 mm before treatment. The test stick result and the quantitative assay were discrepant in only 18 of the 207 sites tested, thus agreement was very good (κ = 0.81). With a threshold of 1 mg/l MMP‐8 activity the chair‐side test provided a sensitivity of 0.83 and specificity of 0.96 (n = 207).Conclusion: The MMP‐8 test can be used to differentiate periodontitis from gingivitis and healthy sites as well as to monitor treatment of periodontitis. A reduction in GCF MMP‐8 levels and a change in test stick result provide a means to optimize patient control during maintenance of periodontal treatment.
Soluble membrane‐type 1 matrix metalloproteinase (MT1‐MMP) and gelatinase A (MMP‐2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis
The aim of this study was to investigate the involvement of the MT1‐MMP/MMP‐2 cascade in induced sputum (IS) and bronchoalveolar lavage fluid (BALF) from bronchial asthma (BA) and bronchiectasis (BE) patients and healthy controls. The molecular forms and cellular origins of MT1‐MMP and MMP‐2 were determined by Western immunoblotting, immunohistochemistry and in situ hybridization. Elevated levels of soluble activated and autocatalyzed MT1‐MMP species as well as activated forms of MMP‐2 in IS and BALF samples from BA and BE patients were evidenced. The activation degrees of soluble MT1‐MMP and MMP‐2 were significantly correlated in BA and BE IS and BALF. Only low levels of both these MMPs were observed in healthy control IS and BALF. The co‐expression of MMP‐2 with MT1‐MMP was evidenced by double immunostaining in bronchial epithelial cells, submucosal glandular cells, smooth muscle cells and monocyte/macrophages. The MT1‐MMP/MMP‐2 cascade is present and active in human inflammatory lung disease fluid and tissue samples. This cascade seemingly reflects the active destructive phases of these chronic lung diseases.
Soluble membrane‐type 1 matrix metalloproteinase (MT1‐MMP) and gelatinase A (MMP‐2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis
The aim of this study was to investigate the involvement of the MT1‐MMP/MMP‐2 cascade in induced sputum (IS) and bronchoalveolar lavage fluid (BALF) from bronchial asthma (BA) and bronchiectasis (BE) patients and healthy controls. The molecular forms and cellular origins of MT1‐MMP and MMP‐2 were determined by Western immunoblotting, immunohistochemistry and in situ hybridization. Elevated levels of soluble activated and autocatalyzed MT1‐MMP species as well as activated forms of MMP‐2 in IS and BALF samples from BA and BE patients were evidenced. The activation degrees of soluble MT1‐MMP and MMP‐2 were significantly correlated in BA and BE IS and BALF. Only low levels of both these MMPs were observed in healthy control IS and BALF. The co‐expression of MMP‐2 with MT1‐MMP was evidenced by double immunostaining in bronchial epithelial cells, submucosal glandular cells, smooth muscle cells and monocyte/macrophages. The MT1‐MMP/MMP‐2 cascade is present and active in human inflammatory lung disease fluid and tissue samples. This cascade seemingly reflects the active destructive phases of these chronic lung diseases.
- 23 April 2001
- Published by Wiley in The Journal of Pathology
- Vol. 194 (2) , 232-238
In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis
The purpose of this study was to determine whether other cellular sources than neutrophils can express matrix metalloproteinase (MMP)‐8 protein and mRNA in bronchiectatic (BE) lung. The molecular forms of MMP‐8 in the BE bronchoalveolar lavage fluid (BALF) and healthy control BALF were analysed by western immunoblotting. MMP‐8 expression was demonstrated by immunohistochemistry and in situ hybridization in BE lung tissue and by immunohistochemistry in control lung tissue. In the BE BALF, different MMP‐8 species were detected: 70–80 kD MMP‐8 apparently of polymorphonuclear leukocyte (PMN) origin and also 40–60 kD MMP‐8 from non‐PMN cellular sources, such as bronchial epithelial cells, glandular cells or monocytes/macrophages. Both of these MMP‐8 species were elevated and converted to a significant extent to activated forms in BE BALF compared with healthy control BALF. The levels of high molecular weight (>80 kD) MMP‐8 complexes, evidently representing MMP‐8 trapped by endogenous MMP inhibitors and/or MMP‐8 dimers, were significantly elevated in BE BALF compared with healthy control BALF. In BE lung tissue, the MMP‐8 protein and mRNA expression was found in bronchial ciliated epithelial cells, glandular cells, neutrophils, and monocytes/macrophages infiltrating the bronchial epithelial area. Minimal MMP‐8 expression was observed in neutrophils, monocytes/macrophages, and epithelial cells in control lung tissues. In this study, new potential cellular sources have been demonstrated for MMP‐8 in the inflamed lung. MMP‐8 from multiple cellular sources, including inflamed lung epithelium, was activated to a significant extent in the BE BALF, indicating a major role for MMP‐8 in the destruction of lung and bronchial tissues. Copyright © 2001 John Wiley & Sons, Ltd.
- 23 April 2001
- Published by Wiley in The Journal of Pathology
- Vol. 194 (2) , 232-238
In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis
The purpose of this study was to determine whether other cellular sources than neutrophils can express matrix metalloproteinase (MMP)‐8 protein and mRNA in bronchiectatic (BE) lung. The molecular forms of MMP‐8 in the BE bronchoalveolar lavage fluid (BALF) and healthy control BALF were analysed by western immunoblotting. MMP‐8 expression was demonstrated by immunohistochemistry and in situ hybridization in BE lung tissue and by immunohistochemistry in control lung tissue. In the BE BALF, different MMP‐8 species were detected: 70–80 kD MMP‐8 apparently of polymorphonuclear leukocyte (PMN) origin and also 40–60 kD MMP‐8 from non‐PMN cellular sources, such as bronchial epithelial cells, glandular cells or monocytes/macrophages. Both of these MMP‐8 species were elevated and converted to a significant extent to activated forms in BE BALF compared with healthy control BALF. The levels of high molecular weight (>80 kD) MMP‐8 complexes, evidently representing MMP‐8 trapped by endogenous MMP inhibitors and/or MMP‐8 dimers, were significantly elevated in BE BALF compared with healthy control BALF. In BE lung tissue, the MMP‐8 protein and mRNA expression was found in bronchial ciliated epithelial cells, glandular cells, neutrophils, and monocytes/macrophages infiltrating the bronchial epithelial area. Minimal MMP‐8 expression was observed in neutrophils, monocytes/macrophages, and epithelial cells in control lung tissues. In this study, new potential cellular sources have been demonstrated for MMP‐8 in the inflamed lung. MMP‐8 from multiple cellular sources, including inflamed lung epithelium, was activated to a significant extent in the BE BALF, indicating a major role for MMP‐8 in the destruction of lung and bronchial tissues. Copyright © 2001 John Wiley & Sons, Ltd.
- 1 June 1999
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 878 (1) , 130-140
Scientific Basis of a Matrix Metalloproteinase‐8 Specific Chair‐side Test for Monitoring Periodontal and Peri‐implant Health and Disease
Matrix metalloproteinases (MMPs), especially collagenase‐2 (MMP‐8), are key mediators of irreversible tissue destruction associated with periodontitis and peri‐implantitis. MMP‐8 is known to exist in elevated amounts and in active form in the gingival crevicular fluid (GCF) and peri‐im‐plant sulcular fluid (PISF) from progressing periodontitis and peri‐implantitis lesions and sites, respectively. (Sorsa et al. Ann. N.Y. Acad. Sci. 737: 112‐131 [1994]; Teronen et al. J. Dent. Res. 76: 1529‐1537 [1997]). We have developed monoclonal antibodies to MMP‐8 (Hanemaaijer et al. J. Biol. Chem. 272: 31504‐31509 [1997]) that can be used in a chair‐side dipstick test to monitor the course and treatment of periodontitis and peri‐implantitis. Monoclonal and polyclonal antibody tests for MMP‐8 coincided with the classical functional collagenase activity test from GCF and PISF (Sorsa et al. J. Periodont.Res. 22: 386‐393 [1988]) in periodontal and peri‐implant health and disease. In future a chair‐side functional and/or immunological MMP‐test can be useful to diagnose and monitor periodontal and peri‐implant disease and health.
- 1 June 1999
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 878 (1) , 130-140
Scientific Basis of a Matrix Metalloproteinase‐8 Specific Chair‐side Test for Monitoring Periodontal and Peri‐implant Health and Disease
Matrix metalloproteinases (MMPs), especially collagenase‐2 (MMP‐8), are key mediators of irreversible tissue destruction associated with periodontitis and peri‐implantitis. MMP‐8 is known to exist in elevated amounts and in active form in the gingival crevicular fluid (GCF) and peri‐im‐plant sulcular fluid (PISF) from progressing periodontitis and peri‐implantitis lesions and sites, respectively. (Sorsa et al. Ann. N.Y. Acad. Sci. 737: 112‐131 [1994]; Teronen et al. J. Dent. Res. 76: 1529‐1537 [1997]). We have developed monoclonal antibodies to MMP‐8 (Hanemaaijer et al. J. Biol. Chem. 272: 31504‐31509 [1997]) that can be used in a chair‐side dipstick test to monitor the course and treatment of periodontitis and peri‐implantitis. Monoclonal and polyclonal antibody tests for MMP‐8 coincided with the classical functional collagenase activity test from GCF and PISF (Sorsa et al. J. Periodont.Res. 22: 386‐393 [1988]) in periodontal and peri‐implant health and disease. In future a chair‐side functional and/or immunological MMP‐test can be useful to diagnose and monitor periodontal and peri‐implant disease and health.
- Open Access
- 1 August 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (34) , 21067-21074
Activation of Type IV Procollagenases by Human Tumor-associated Trypsin-2
- 1 August 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (34) , 21067-21074
Open AccessActivation of Type IV Procollagenases by Human Tumor-associated Trypsin-2